Intra-Cellular Therapies

Neuroscience-focused biopharma (Caplyta/lumateperone), acquired by Johnson & Johnson April 2025 for ~$14.6B

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Lumateperone(Caplyta)
Approved
Serotonin 5-HT2A / dopamine D1-D2 receptorSmall molecule
Major Depressive DisorderSchizophreniaBipolar Depression
Phase 3
Serotonin 5-HT2A / dopamine D1-D2 receptorSmall molecule
Alzheimer's DiseaseGeneralized Anxiety Disorder
Alzheimer's Disease Agitation

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
March 2027 (1)
DeulumateperonePhase 2Generalized Anxiety Disorder
Est. primary completion 2027-03-16 · NCT06480383 · CT.gov ↗
What to watch
April 2027 (1)
Lumateperone · CaplytaPhase 3Major Depressive Disorder
Est. primary completion 2027-04-05 · NCT05850689 · CT.gov ↗
What to watch
June 2027 (2)
Lumateperone · CaplytaPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2027-06-21 · NCT06690398 · CT.gov ↗
What to watch
Lumateperone · CaplytaPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2027-06-21 · NCT06706674 · CT.gov ↗
What to watch
October 2027 (1)
DeulumateperonePhase 2Generalized Anxiety Disorder
Est. primary completion 2027-10-14 · NCT06701903 · CT.gov ↗
What to watch
December 2027 (1)
DeulumateperonePhase 2Agitation Associated With Alzheimer's Dementia
Est. primary completion 2027-12-28 · NCT06651567 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
DeulumateperonePhase 2Psychotic Disorders, Alzheimer Disease
Est. primary completion 2028-09-30 · NCT06540833 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
Lumateperone · CaplytaPhase 3Depressive Disorder, Major
Est. primary completion 2029-09-20 · NCT07747389 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
DeulumateperonePhase 3Generalized Anxiety Disorder
Est. primary completion 2030-02-18 · NCT07807865 · CT.gov ↗
What to watch
September 2030 (1)
DeulumateperonePhase 3Generalized Anxiety Disorder
Est. primary completion 2030-09-20 · NCT07856420 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Lumateperone · CaplytaPhase 3Bipolar Depression
Est. primary completion 2031-10-31 · NCT06372964 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Lumateperone · CaplytaPhase 3Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Est. primary completion 2032-04-28 · NCT06229210 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 September 2026Topline resultLumateperoneStudy 451 phase 3 topline
Johnson & Johnson · Source ↗
27 April 2026ApprovalLumateperoneFDA approves CAPLYTA sNDA for relapse prevention in schizophrenia
US, FDA · Source ↗
6 November 2025ApprovalLumateperoneFDA approves CAPLYTA for adjunctive treatment of MDD
US, FDA · Source ↗
5 November 2025ApprovalLumateperoneFDA Boxed Warning on Caplyta (NDA209500)
US, FDA · FDA · Source ↗
8 July 2025Filing submittedLumateperoneJohnson & Johnson submits a CAPLYTA sNDA for schizophrenia relapse prevention
US, FDA · Johnson & Johnson · Source ↗

Financial reports

No financial reports recorded.